The ROE as of November 2024 (TTM) for Oncotelic Therapeutics, Inc. (OTLC) is -10.18%

According to Oncotelic Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -10.18%. This represents a change of 294.44% compared to the average of -2.58% of the last 4 quarters.

Oncotelic Therapeutics, Inc. (OTLC) Historical ROE (quarterly & annually)

How has OTLC ROE performed in the past?

The mean historical ROE of Oncotelic Therapeutics, Inc. over the last ten years is 318.70%. The current -10.18% ROE has changed -103.20% with respect to the historical average. Over the past ten years (40 quarters), OTLC's ROE was at its highest in in the December 2017 quarter at 510.27%. The ROE was at its lowest in in the September 2018 quarter at -1163.79%.

Oncotelic Therapeutics, Inc. (OTLC) ROE by Quarter and Year

Discovering the peaks and valleys of Oncotelic Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Oncotelic Therapeutics, Inc. (OTLC) Average ROE

How has OTLC ROE performed in the past?

The current ROE of Oncotelic Therapeutics, Inc. (OTLC) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Oncotelic Therapeutics, Inc. (OTLC) ROE vs. Peers

How is OTLC’s ROE compared to its peers?

Oncotelic Therapeutics, Inc.’s ROE is greater than Ceapro Inc. (-21.67%), less than PhaseBio Pharmaceuticals, Inc. (0.22%), greater than Processa Pharmaceuticals, Inc. (-195.22%), less than Kaleido Biosciences, Inc. (0%), less than Advanced Proteome Therapeutics Corporation (0%), greater than Cellectis S.A. (-81.02%), less than ChitogenX Inc. (27.19%), greater than Biotron Limited (-504.53%), less than Bioasis Technologies Inc. (0%), less than Nascent Biotech, Inc. (1.03%), greater than ProtoKinetix, Incorporated (-87.94%), less than RespireRx Pharmaceuticals Inc. (8.92%), greater than Silo Pharma, Inc. (-56.41%), less than VG Life Sciences Inc. (2.26%), less than Rubius Therapeutics, Inc. (0%), greater than Peak Bio, Inc. (-519.01%), less than AlloVir, Inc. (0%), less than null (23.48%), greater than null (-96.48%),

Build a custom stock screener for Oncotelic Therapeutics, Inc. (OTLC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncotelic Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oncotelic Therapeutics, Inc. (OTLC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oncotelic Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.